Introgen Therapeutics, Inc.
New developments from Introgen Therapeutics, Inc., highlighted recently
Published in Medicine and Law Weekly, August 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Introgen Therapeutics, Inc.
Report 1: Introgen Therapeutics, Inc. (NASDAQ:INGN) reported promising Phase 1/2 clinical data with INGN 241, the Company's novel investigational mda-7/IL-24 tumor suppressor agent, in patients with advanced solid tumors.
The data (Abstract #380), which were presented today at the annual meeting of the American Society of Gene Therapy, showed that in this 22-patient trial, INGN 241 induced killing in all treated tumors, including...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Anemia
Reports outline anemia in children research from Johns Hopkins University, Department of International Health - Chromatography
New findings from Hunan University in the area of chromatography published - Clinical Trial Research
Studies from Royal University have provided new information about clinical trial research in children - Criminology
Researchers from University of Oxford describe findings in criminology - Drug Abuse
Scientists at Taipei Medical University discuss research in drug abuse - Escherichia coli
Recent findings in escherichia coli described by L.S.S. Barros and colleagues - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
